<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ERYTHROMYCIN- erythromycin gel </strong><br>E. FOUGERA &amp; CO., A division of Fougera Pharmaceuticals Inc.<br></p></div>
<h1>Erythromycin Topical Gel USP, 2%</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s1"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
<p><span class="Bold">FOR DERMATOLOGIC USE ONLY   NOT FOR OPHTHALMIC USE</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION:</h1>
<p class="First">Erythromycin Topical Gel contains erythromycin for topical dermatologic use. Erythromycin is a macrolide antibiotic produced from a <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of <span class="Italics">Saccaropolyspora erythraea</span> (formerly <span class="Italics">Streptomyces erythreus</span>). It is a base and readily forms salts with acids. Chemically, erythromycin is: (3<span class="Italics">R</span>*,4<span class="Italics">S</span>*,5<span class="Italics">S</span>*,6<span class="Italics">R</span>*,7<span class="Italics">R</span>*,9<span class="Italics">R</span>*,11<span class="Italics">R</span>*,12<span class="Italics">R</span>*, 13<span class="Italics">S</span>*,14<span class="Italics">R</span>*)-4-[(2,6-Dideoxy-3-<span class="Italics">C</span>-methyl-3-<span class="Italics">O</span>-methyl-<span class="Italics">α</span>-L-<span class="Italics">ribo</span>-hexopyranosyl)-oxy]-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethylamino)-<span class="Italics">β</span>-D-<span class="Italics">xylo</span>-hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione. It has the following structural formula:</p>
<div class="Figure">
<a name="f1"></a><img alt="Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=aa993373-f75f-440f-bdae-59892557ba2c&amp;name=erythromycin-topical-gel-01.jpg">
</div>
<p>Erythromycin is a white or slightly yellow crystalline powder that is very soluble in water, freely soluble in alcohols, acetone, chloroform, acetonitrile, ethyl acetate, and moderately soluble in ether, ethylene dichloride and amyl acetate.</p>
<p>Each gram of Erythromycin Topical Gel 2% contains: Active Ingredient: erythromycin USP, 2% (20 mg/g). Inactive Ingredients: alcohol USP, 92% and hydroxypropyl cellulose NF.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s3"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY:</h1>
<p class="First">The exact mechanism by which erythromycin reduces lesions of <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span> is not fully known; however, the effect appears to be due in part to the antibacterial activity of the drug.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s4"></a><a name="section-3.1"></a><p></p>
<p class="First"><span class="Bold">Microbiology:</span> Erythromycin acts by inhibition of protein synthesis in susceptible organisms by reversibly binding to 50 S ribosomal subunits, thereby inhibiting translocation of aminoacyl transfer-RNA and inhibiting polypeptide synthesis. Antagonism has been demonstrated <span class="Italics">in vitro</span> between erythromycin, lincomycin, chloramphenicol, and clindamycin.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s5"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE:</h1>
<p class="First">Erythromycin Topical Gel is indicated for the topical treatment of <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s6"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS:</h1>
<p class="First">Erythromycin Topical Gel is contraindicated in those individuals who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of its components.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s7"></a><a name="section-6"></a><p></p>
<h1>WARNINGS:</h1>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">Pseudomembranous colitis</span> has been reported with nearly all antibacterial agents, including erythromycin, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> subsequent to the administration of antibacterial agents.</span></p>
<p>Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by <span class="Italics">Clostridium difficile</span> is one primary cause of ``antibiotic-associated colitis′′.</p>
<p>After the diagnosis of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> has been established, therapeutic measures should be initiated. Mild cases of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> usually respond to drug discontinuation alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation and treatment with an antibacterial drug clinically effective against <span class="Italics">C. difficile</span> <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s8"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS:</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s9"></a><a name="section-7.1"></a><p></p>
<p class="First"><span class="Bold">General:</span> For topical use only; not for ophthalmic use. Concomitant topical <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> therapy should be used with caution because a possible cumulative irritancy effect may occur, especially with the use of <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span>, desquamating or abrasive agents.</p>
<p>The use of antibiotic agents may be associated with the overgrowth of antibiotic-resistant organisms. If this occurs, discontinue use and take appropriate measures. Avoid contact with eyes and all mucous membranes.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s10"></a><a name="section-7.2"></a><p></p>
<p class="First"><span class="Bold">Information for Patients:</span> Patients using Erythromycin Topical Gel should receive the following information and instructions:</p>
<ol class="Arabic">
<li>This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes, nose, mouth, and all mucous membranes.</li>
<li>This medication should not be used for any disorder other than that for which it was prescribed.</li>
<li>Patients should not use any other topical <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> medication unless otherwise directed by their physician.</li>
<li>Patients should report to their physician any signs of local adverse reactions.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s11"></a><a name="section-7.3"></a><p></p>
<p class="First"><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility:</span> No animal studies have been performed to evaluate the carcinogenic and mutagenic potential or effects on fertility of topical erythromycin. However, long-term (2 years) oral studies in rats with erythromycin ethylsuccinate and erythromycin base did not provide evidence of tumorigenicity. There was no apparent effect on male or female fertility in rats fed erythromycin (base) at levels up to 0.25% of diet.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s12"></a><a name="section-7.4"></a><p></p>
<p class="First"><span class="Bold">Pregnancy:</span><span class="Underline">Teratogenic effects</span>–<span class="Italics">Pregnancy Category B</span>. There was no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> or any other adverse effect on reproduction in female rats fed erythromycin base (up to 0.25% of diet) prior to and during mating, during gestation and through weaning of two successive litters.</p>
<p>There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used in pregnancy only if clearly needed. Erythromycin has been reported to cross the placental barrier in humans, but fetal plasma levels are generally low.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s13"></a><a name="section-7.5"></a><p></p>
<p class="First"><span class="Bold">Nursing Mothers:</span> It is not known whether erythromycin is excreted in human milk after topical application. However, erythromycin is excreted in human milk following oral and parenteral erythromycin administration. Therefore, caution should be exercised when erythromycin is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s14"></a><a name="section-7.6"></a><p></p>
<p class="First"><span class="Bold">Pediatric Use:</span> Safety and effectiveness of this product in pediatric patients have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s15"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS:</h1>
<p class="First">The most common adverse reaction reported with Erythromycin Topical Gel was burning.</p>
<p>The following local adverse reactions have been reported occasionally: <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span>, dryness, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, and oiliness. Irritation of the eyes and <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> of the skin have also been reported with topical use of erythromycin. Generalized urticarial reactions possibly related to the use of erythromycin, which required systemic steroid therapy have been reported.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s16"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION:</h1>
<p class="First">Apply sparingly as a thin film to affected area(s) once or twice a day after the skin is thoroughly cleansed and patted dry. If there has been no improvement after 6 to 8 weeks, or if the condition becomes worse, treatment should be discontinued, and the physician should be reconsulted. Spread the medication lightly rather than rubbing it In. The hands should be washed after application. There are no data directly comparing the safety and efficacy of b.i.d. versus q.d. dosing.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s17"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED:</h1>
<p class="First">Erythromycin Topical Gel USP, 2% is supplied as follows:</p>
<p>30 gram tubes - NDC 0168-0216-30      60 gram tubes - NDC 0168-0216-60</p>
<p><span class="Bold">NOTE: FLAMMABLE. Keep away from heat and flame.</span></p>
<p>Store and dispense in original container.</p>
<p>Keep tube tightly closed.</p>
<p>Store between 15° and 25°C (59° and 77°F).</p>
<p><span class="Bold">E. FOUGERA &amp; CO.</span><br>A division of Fougera Pharmaceuticals Inc.<br>Melville, New York 11747</p>
<p>I2216C<br>R12/11<br>#153</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s18"></a><a name="section-11"></a><p></p>
<h1>PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 30 G CONTAINER
</h1>
<p class="First">NDC 0168-0216-30
</p>
<p>FOUGERA<span class="Sup">®</span></p>
<p><span class="Bold">ERYTHROMYCIN</span></p>
<p><span class="Bold">TOPICAL GEL<br>USP, 2%</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">FOR DERMATOLOGIC USE ONLY.</span></p>
<p><span class="Bold">NOT FOR OPHTHALMIC USE.</span></p>
<p>Active Ingredient: erythromycin <br>USP, 20 mg/g
</p>
<p>Inactive Ingredients: alcohol USP<br> 92% and hydroxypropyl cellulose NF.
</p>
<p><span class="Bold">NET WT 30 grams</span></p>
<div class="Figure">
<a name="f02"></a><img alt="PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 30 G CONTAINER
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=aa993373-f75f-440f-bdae-59892557ba2c&amp;name=erythromycin-topical-gel-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s19"></a><a name="section-12"></a><p></p>
<h1>PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 30 G CARTON
</h1>
<p class="First">NDC 0168-0216-30   <span class="Bold">R</span>x only
</p>
<p>FOUGERA<span class="Sup">®</span></p>
<p><span class="Bold">ERYTHROMYCIN </span></p>
<p><span class="Bold">TOPICAL GEL USP, 2%</span></p>
<p><span class="Bold">FOR DERMATOLOGIC USE ONLY.</span></p>
<p><span class="Bold">NOT FOR OPHTHALMIC USE.</span></p>
<p><span class="Bold">NET WT 30 grams</span></p>
<div class="Figure">
<a name="f03"></a><img alt="PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 30 G CARTON
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=aa993373-f75f-440f-bdae-59892557ba2c&amp;name=erythromycin-topical-gel-03.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ERYTHROMYCIN 		
					</strong><br><span class="contentTableReg">erythromycin gel</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0168-0216</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ERYTHROMYCIN</strong> (ERYTHROMYCIN) </td>
<td class="formItem">ERYTHROMYCIN</td>
<td class="formItem">20 mg  in 1 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0168-0216-30</td>
<td class="formItem">30 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0168-0216-60</td>
<td class="formItem">60 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA064184</td>
<td class="formItem">09/30/1997</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>E. FOUGERA &amp; CO., A division of Fougera Pharmaceuticals Inc.
							(043838424)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Fougera Pharmaceuticals Inc.</td>
<td class="formItem"></td>
<td class="formItem">174491316</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Fougera Pharmaceuticals Inc.</td>
<td class="formItem"></td>
<td class="formItem">043838424</td>
<td class="formItem">ANALYSIS</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>2a20dc13-a010-4cc8-a08a-7215c6cc58f7</div>
<div>Set id: aa993373-f75f-440f-bdae-59892557ba2c</div>
<div>Version: 4</div>
<div>Effective Time: 20120607</div>
</div>
</div> <div class="DistributorName">E. FOUGERA &amp; CO., A division of Fougera Pharmaceuticals Inc.</div></p>
</body></html>
